Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Somatic gene mutation detection system

PMA Number: P170005 · 2026-05-28

ApplicantAbbott Molecular, Inc.
Decision Date2026-05-28
PMA NumberP170005
Product CodeOWD
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeMG

Device Summary

Somatic gene mutation detection system is the device name listed in this FDA 510(k) record. The listed applicant is Abbott Molecular, Inc.. It received FDA 510(k) clearance on 2026-05-28. The device is classified under product code OWD. It was reviewed by the MG advisory panel.

Frequently Asked Questions

What is the Somatic gene mutation detection system?

Somatic gene mutation detection system is a medical device that received FDA 510(k) clearance on 2026-05-28. The listed applicant is Abbott Molecular, Inc..

When did Somatic gene mutation detection system receive FDA 510(k) clearance?

The clearance date for Somatic gene mutation detection system can be found in the official FDA records.

Who is the listed applicant for Somatic gene mutation detection system?

The FDA 510(k) record lists Abbott Molecular, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Somatic gene mutation detection system?

The FDA product code for Somatic gene mutation detection system is OWD.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑